Logo image of OFIX

ORTHOFIX MEDICAL INC (OFIX) Stock Fundamental Analysis

NASDAQ:OFIX - Nasdaq - US68752M1080 - Common Stock - Currency: USD

17.95  -0.15 (-0.83%)

After market: 17.95 0 (0%)

Fundamental Rating

3

Overall OFIX gets a fundamental rating of 3 out of 10. We evaluated OFIX against 189 industry peers in the Health Care Equipment & Supplies industry. OFIX may be in some trouble as it scores bad on both profitability and health. OFIX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year OFIX was profitable.
OFIX had a negative operating cash flow in the past year.
In the past 5 years OFIX reported 4 times negative net income.
In multiple years OFIX reported negative operating cash flow during the last 5 years.
OFIX Yearly Net Income VS EBIT VS OCF VS FCFOFIX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M -100M -150M

1.2 Ratios

OFIX has a Return On Assets (-13.71%) which is comparable to the rest of the industry.
OFIX has a Return On Equity of -22.63%. This is comparable to the rest of the industry: OFIX outperforms 59.04% of its industry peers.
Industry RankSector Rank
ROA -13.71%
ROE -22.63%
ROIC N/A
ROA(3y)-9.57%
ROA(5y)-6.8%
ROE(3y)-14.18%
ROE(5y)-10.11%
ROIC(3y)N/A
ROIC(5y)N/A
OFIX Yearly ROA, ROE, ROICOFIX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10 -20

1.3 Margins

OFIX has a better Gross Margin (68.05%) than 76.06% of its industry peers.
OFIX's Gross Margin has declined in the last couple of years.
OFIX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.05%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.57%
GM growth 5Y-3.71%
OFIX Yearly Profit, Operating, Gross MarginsOFIX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 60

More info and screens

3

2. Health

2.1 Basic Checks

OFIX does not have a ROIC to compare to the WACC, probably because it is not profitable.
OFIX has more shares outstanding than it did 1 year ago.
OFIX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for OFIX is higher compared to a year ago.
OFIX Yearly Shares OutstandingOFIX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
OFIX Yearly Total Debt VS Total AssetsOFIX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of 1.69, we must say that OFIX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of OFIX (1.69) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.25 indicates that OFIX is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.25, OFIX is in line with its industry, outperforming 51.60% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Altman-Z 1.69
ROIC/WACCN/A
WACC8.84%
OFIX Yearly LT Debt VS Equity VS FCFOFIX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M

2.3 Liquidity

OFIX has a Current Ratio of 2.39. This indicates that OFIX is financially healthy and has no problem in meeting its short term obligations.
OFIX has a Current ratio (2.39) which is in line with its industry peers.
OFIX has a Quick Ratio of 1.11. This is a normal value and indicates that OFIX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.11, OFIX is doing worse than 72.87% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.39
Quick Ratio 1.11
OFIX Yearly Current Assets VS Current LiabilitesOFIX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

5

3. Growth

3.1 Past

OFIX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -94.44%.
Measured over the past years, OFIX shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -64.57% on average per year.
The Revenue has grown by 17.33% in the past year. This is quite good.
Measured over the past years, OFIX shows a quite strong growth in Revenue. The Revenue has been growing by 10.51% on average per year.
EPS 1Y (TTM)-94.44%
EPS 3Y-65.8%
EPS 5Y-64.57%
EPS Q2Q%0%
Revenue 1Y (TTM)17.33%
Revenue growth 3Y22.46%
Revenue growth 5Y10.51%
Sales Q2Q%6.85%

3.2 Future

The Earnings Per Share is expected to grow by 217.35% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 6.60% on average over the next years.
EPS Next Y-1324%
EPS Next 2Y-124.94%
EPS Next 3Y217.35%
EPS Next 5YN/A
Revenue Next Year7.41%
Revenue Next 2Y6.87%
Revenue Next 3Y6.7%
Revenue Next 5Y6.6%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
OFIX Yearly Revenue VS EstimatesOFIX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M
OFIX Yearly EPS VS EstimatesOFIX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.5 1 1.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 1795.00 indicates a quite expensive valuation of OFIX.
Compared to the rest of the industry, the Price/Earnings ratio of OFIX indicates a somewhat cheap valuation: OFIX is cheaper than 63.30% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of OFIX to the average of the S&P500 Index (29.62), we can say OFIX is valued expensively.
The Forward Price/Earnings Ratio is negative for OFIX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 1795
Fwd PE N/A
OFIX Price Earnings VS Forward Price EarningsOFIX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 500 -500 1K 1.5K

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OFIX Per share dataOFIX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

A more expensive valuation may be justified as OFIX's earnings are expected to grow with 217.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-124.94%
EPS Next 3Y217.35%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for OFIX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ORTHOFIX MEDICAL INC

NASDAQ:OFIX (2/21/2025, 8:00:01 PM)

After market: 17.95 0 (0%)

17.95

-0.15 (-0.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)02-25 2025-02-25/bmo
Inst Owners88.71%
Inst Owner Change-92.38%
Ins Owners1.69%
Ins Owner Change-0.74%
Market Cap685.87M
Analysts81.67
Price Target24.79 (38.11%)
Short Float %1.85%
Short Ratio3.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)135.55%
Min EPS beat(2)125.36%
Max EPS beat(2)145.75%
EPS beat(4)4
Avg EPS beat(4)114.65%
Min EPS beat(4)61.76%
Max EPS beat(4)145.75%
EPS beat(8)8
Avg EPS beat(8)107.08%
EPS beat(12)10
Avg EPS beat(12)61.24%
EPS beat(16)13
Avg EPS beat(16)107.74%
Revenue beat(2)0
Avg Revenue beat(2)-1.09%
Min Revenue beat(2)-1.92%
Max Revenue beat(2)-0.26%
Revenue beat(4)2
Avg Revenue beat(4)-0.29%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)0.6%
Revenue beat(8)3
Avg Revenue beat(8)-2.58%
Revenue beat(12)3
Avg Revenue beat(12)-2.14%
Revenue beat(16)6
Avg Revenue beat(16)-0.56%
PT rev (1m)-0.41%
PT rev (3m)-0.41%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.96%
EPS NY rev (1m)5.27%
EPS NY rev (3m)47.83%
Revenue NQ rev (1m)-0.06%
Revenue NQ rev (3m)-0.06%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)-0.05%
Valuation
Industry RankSector Rank
PE 1795
Fwd PE N/A
P/S 0.87
P/FCF N/A
P/OCF N/A
P/B 1.3
P/tB 3.03
EV/EBITDA N/A
EPS(TTM)0.01
EY0.06%
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-1.2
FCFYN/A
OCF(TTM)-0.12
OCFYN/A
SpS20.52
BVpS13.76
TBVpS5.93
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.71%
ROE -22.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.05%
FCFM N/A
ROA(3y)-9.57%
ROA(5y)-6.8%
ROE(3y)-14.18%
ROE(5y)-10.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.57%
GM growth 5Y-3.71%
F-Score4
Asset Turnover0.9
Health
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 71.33%
Cap/Sales 5.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.39
Quick Ratio 1.11
Altman-Z 1.69
F-Score4
WACC8.84%
ROIC/WACCN/A
Cap/Depr(3y)90.56%
Cap/Depr(5y)88.81%
Cap/Sales(3y)6.04%
Cap/Sales(5y)5.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-94.44%
EPS 3Y-65.8%
EPS 5Y-64.57%
EPS Q2Q%0%
EPS Next Y-1324%
EPS Next 2Y-124.94%
EPS Next 3Y217.35%
EPS Next 5YN/A
Revenue 1Y (TTM)17.33%
Revenue growth 3Y22.46%
Revenue growth 5Y10.51%
Sales Q2Q%6.85%
Revenue Next Year7.41%
Revenue Next 2Y6.87%
Revenue Next 3Y6.7%
Revenue Next 5Y6.6%
EBIT growth 1Y34.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year146.77%
EBIT Next 3Y39.3%
EBIT Next 5Y29.74%
FCF growth 1Y-75.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-120.67%
OCF growth 3YN/A
OCF growth 5YN/A